본문 바로가기

추천 검색어

실시간 인기 검색어

학술논문

Dosimetric advantages and clinical outcomes of simultaneous integrated boost intensity-modulated radiotherapy for anal squamous cell carcinoma

이용수  6

영문명
발행기관
대한방사선종양학회
저자명
Katsuyuki Sakanaka Satoshi Itasaka Yuichi Ishida Kota Fujii Takahiro Horimatsu Takashi Mizowaki Yoshiharu Sakai Masahiro Hiraoka
간행물 정보
『대한방사선종양학회지』제35권 제4호, 368~379쪽, 전체 12쪽
주제분류
의약학 > 종양학
파일형태
PDF
발행일자
2017.12.30
4,240

구매일시로부터 72시간 이내에 다운로드 가능합니다.
이 학술논문 정보는 (주)교보문고와 각 발행기관 사이에 저작물 이용 계약이 체결된 것으로, 교보문고를 통해 제공되고 있습니다.

1:1 문의
논문 표지

국문 초록

영문 초록

Purpose: The purpose of this study was to explore the dosimetric difference between simultaneous integrated boost intensitymodulated radiotherapy (SIB-IMRT) and three-dimensional conformal radiotherapy (3DCRT), and the clinical outcomes of anal squamous cell carcinoma (ASCC) chemoradiotherapy featuring SIB-IMRT. Materials and Methods: This study included ten patients with ASCC who underwent chemoradiotherapy using SIB-IMRT with 5-fluorouracil and mitomycin C. SIB-IMRT delivered 54 Gy to each primary tumor plus metastatic lymph nodes and 45 Gy to regional lymph nodes, in 30 fractions. Four patients received additional boosts to the primary tumors and metastatic lymph nodes; the median total dose was 54 Gy (range, 54 to 60 Gy). We additionally created 3DCRT plans following the Radiation Therapy Oncology Group 9811 protocol to allow dosimetric comparisons with SIB-IMRT. Locoregional control, overall survival, and toxicity were calculated for the clinical outcome evaluation. Results: Compared to 3DCRT, SIB-IMRT significantly reduced doses to the external genitalia, bladder, and intestine, delivering the doses to target and elective nodal region. At a median follow-up time of 46 months, 3-year locoregional control and overall survival rates were 88.9% and 100%, respectively. Acute toxicities were treated conservatively. All patients completed radiotherapy with brief interruptions (range, 0 to 2 days). No patient experienced ≥grade 3 late toxicity during the follow-up period. Conclusion: The dosimetric advantages of SIB-IMRT appeared to reduce the toxicity of chemoradiotherapy for ASCC achieving high locoregional control in the extended period.

목차

Abstract
Introduction
Materials and Methods
Results
Discussion and Conclusion
Conflict of Interest
Acknowledgments
References

키워드

해당간행물 수록 논문

참고문헌

교보eBook 첫 방문을 환영 합니다!

신규가입 혜택 지급이 완료 되었습니다.

바로 사용 가능한 교보e캐시 1,000원 (유효기간 7일)
지금 바로 교보eBook의 다양한 콘텐츠를 이용해 보세요!

교보e캐시 1,000원
TOP
인용하기
APA

Katsuyuki Sakanaka,Satoshi Itasaka,Yuichi Ishida,Kota Fujii,Takahiro Horimatsu,Takashi Mizowaki,Yoshiharu Sakai,Masahiro Hiraoka. (2017).Dosimetric advantages and clinical outcomes of simultaneous integrated boost intensity-modulated radiotherapy for anal squamous cell carcinoma. 대한방사선종양학회지, 35 (4), 368-379

MLA

Katsuyuki Sakanaka,Satoshi Itasaka,Yuichi Ishida,Kota Fujii,Takahiro Horimatsu,Takashi Mizowaki,Yoshiharu Sakai,Masahiro Hiraoka. "Dosimetric advantages and clinical outcomes of simultaneous integrated boost intensity-modulated radiotherapy for anal squamous cell carcinoma." 대한방사선종양학회지, 35.4(2017): 368-379

결제완료
e캐시 원 결제 계속 하시겠습니까?
교보 e캐시 간편 결제